These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 1689956)

  • 1. More information on the visual compatibility of hetastarch with injectable critical-care drugs.
    Wohlford JG; Wright JC; Wilson MR
    Am J Hosp Pharm; 1990 Feb; 47(2):297-8. PubMed ID: 1689956
    [No Abstract]   [Full Text] [Related]  

  • 2. Visual compatibility of hetastarch with injectable critical-care drugs.
    Wohlford JG; Fowler MD
    Am J Hosp Pharm; 1989 May; 46(5):995-6. PubMed ID: 2471410
    [No Abstract]   [Full Text] [Related]  

  • 3. Clarification of visual compatibility of hetastarch and ranitidine hydrochloride.
    Wohlford JG
    Am J Hosp Pharm; 1989 Sep; 46(9):1772. PubMed ID: 2478014
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of visual and turbidimetric methods for determining short-term compatibility of intravenous critical-care drugs.
    Dasta JF; Hale KN; Stauffer GL; Tschampel MM
    Am J Hosp Pharm; 1988 Nov; 45(11):2361-6. PubMed ID: 3228093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual compatibility of foscarnet with other injectable drugs.
    Lor E; Takagi J
    Am J Hosp Pharm; 1990 Jan; 47(1):157-9. PubMed ID: 2137288
    [No Abstract]   [Full Text] [Related]  

  • 6. Visual compatibility of dobutamine hydrochloride with other injectable drugs.
    Hasegawa GR; Eder JF
    Am J Hosp Pharm; 1984 May; 41(5):949-51. PubMed ID: 6731457
    [No Abstract]   [Full Text] [Related]  

  • 7. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
    Colucci RD; Cobuzzi LE; Halpern NA
    Am J Hosp Pharm; 1988 Jun; 45(6):1357-8. PubMed ID: 3414706
    [No Abstract]   [Full Text] [Related]  

  • 8. Visual compatibility of zidovudine with other injectable drugs during simulated Y-site administration.
    Bashaw ED; Amantea MA; Minor JR; Gallelli JF
    Am J Hosp Pharm; 1988 Dec; 45(12):2532-3. PubMed ID: 3228107
    [No Abstract]   [Full Text] [Related]  

  • 9. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications.
    Forman JK; Souney PF
    Am J Hosp Pharm; 1987 Oct; 44(10):2298-9. PubMed ID: 3687973
    [No Abstract]   [Full Text] [Related]  

  • 10. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs.
    Hasegawa GR; Eder JF
    Am J Hosp Pharm; 1984 Jul; 41(7):1379-80. PubMed ID: 6465154
    [No Abstract]   [Full Text] [Related]  

  • 11. Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs.
    Lee CY; Mauro VF; Alexander KS
    Am J Hosp Pharm; 1990 Mar; 47(3):606-8. PubMed ID: 2107741
    [No Abstract]   [Full Text] [Related]  

  • 12. Biliary excretion of hydroxyethyl starch in man.
    Kalhorn TF; Yacobi A; Sum CY
    Biomed Mass Spectrom; 1984 Apr; 11(4):164-6. PubMed ID: 6203566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyethyl starch. Control of alpha-amylase hydrolysis and its subsequent clinical application.
    Mishler JM
    Acta Haematol Pol; 1980; 11(2):113-6. PubMed ID: 6158825
    [No Abstract]   [Full Text] [Related]  

  • 14. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection.
    Outman WR; Monolakis J
    Am J Hosp Pharm; 1991 Jul; 48(7):1539-41. PubMed ID: 1882889
    [No Abstract]   [Full Text] [Related]  

  • 15. Visual compatibility of cimetidine hydrochloride with common preoperative injectable medications.
    Souney PF; Solomon MA; Stancher D
    Am J Hosp Pharm; 1984 Sep; 41(9):1840-1. PubMed ID: 6496520
    [No Abstract]   [Full Text] [Related]  

  • 16. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
    Halpern NA; Colucci RD; Alicea M; Greenstein R
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):294-7. PubMed ID: 2544533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on hydroxyethyl starch. Part II: Changes of the molecular weight distribution for hydroxyethyl starch types 450/0.7, 450/0.5, 450/0.3, 300/0.4, 200/0.7, 200/0.5, 200/0.3 and 200/0.1 after infusion in serum and urine of volunteers.
    Ferber HP; Nitsch E; Förster H
    Arzneimittelforschung; 1985; 35(3):615-22. PubMed ID: 2581591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost savings from hetastarch use in place of albumin on a cardiothoracic surgery service.
    Stratton TP; Plachetka JR; Gaines JA
    Hosp Formul; 1984 Jul; 19(7):571-2, 579-83. PubMed ID: 10315594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of hetastarch.
    Nakasato SK
    Clin Pharm; 1982; 1(6):509-14. PubMed ID: 6192962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
    Trissel LA; Chandler SW; Folstad JT
    Am J Hosp Pharm; 1990 Nov; 47(11):2525-8. PubMed ID: 2278268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.